Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Rubius Therapeutics, Inc. | ruby-20201231xex23d1.htm |
| EX-32.2 - EX-32.2 - Rubius Therapeutics, Inc. | ruby-20201231xex32d2.htm |
| EX-31.2 - EX-31.2 - Rubius Therapeutics, Inc. | ruby-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Rubius Therapeutics, Inc. | ruby-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Rubius Therapeutics, Inc. | ruby-20201231xex21d1.htm |
| 10-K - 10-K - Rubius Therapeutics, Inc. | ruby-20201231x10k.htm |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Rubius Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pablo J. Cagnoni, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 23, 2021 |
| By: | /s/ Pablo J. Cagnoni |
|
|
| Pablo J. Cagnoni, M.D. |
|
|
| Chief Executive Officer |
| | | (Principal Executive Officer) |